Meningococcal polysaccharide vaccine group W-135

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Menquadfi, Menveo, Nimenrix
Generic Name
Meningococcal polysaccharide vaccine group W-135
DrugBank Accession Number
DB13887
Background

Meningococcal group W-135 polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup W-135. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.

Type
Biotech
Groups
Approved, Experimental, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Meningococcal polysaccharide antigen group W-135
  • neisseria meningitidis group W-135 capsular polysaccharide antigen
  • Neisseria meningitidis group W-135 polysaccharide antigen, A

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETMeningococcal polysaccharide vaccine group W-135 (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (4 mcg/0.5ml)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADETMeningococcal polysaccharide vaccine group W-135 (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (4 mcg/0.5ml)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADETMeningococcal polysaccharide vaccine group W-135 (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (50 mcg/0.5ml)Injection, powder, for solutionSubcutaneousPFİZER PFE İLAÇLARI A.Ş.2020-08-142019-07-01Turkey flag
Menomune - A/c/y/w-135 CombinedMeningococcal polysaccharide vaccine group W-135 (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group A (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (50 ug/0.5mL)SubcutaneousSanofi Pasteur Inc.1981-11-232017-09-10US flag
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group W-135 (500 mcg / kit) + Meningococcal polysaccharide vaccine group A (500 mcg / kit) + Meningococcal polysaccharide vaccine group C (500 mcg / kit) + Meningococcal polysaccharide vaccine group Y (500 mcg / kit)Powder, for solutionSubcutaneousSanofi Pasteur Limited1983-12-312017-04-05Canada flag
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group W-135 (2.5 mg / kit) + Meningococcal polysaccharide vaccine group A (2.5 mg / kit) + Meningococcal polysaccharide vaccine group C (2.5 mg / kit) + Meningococcal polysaccharide vaccine group Y (2.5 mg / kit)Powder, for solutionSubcutaneousAventis Pasteur Limited1998-08-132006-07-17Canada flag
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group W-135 (50 mcg / 0.5 mL) + Meningococcal polysaccharide vaccine group A (50 mcg / 0.5 mL) + Meningococcal polysaccharide vaccine group C (50 mcg / 0.5 mL) + Meningococcal polysaccharide vaccine group Y (50 mcg / 0.5 mL)Kit; Powder, for solutionSubcutaneousSanofi Pasteur Limited1993-10-292017-04-05Canada flag
MenquadfiMeningococcal polysaccharide vaccine group W-135 (10 mcg) + Meningococcal polysaccharide vaccine group A (10 mcg) + Meningococcal polysaccharide vaccine group C (10 mcg) + Meningococcal polysaccharide vaccine group Y (10 mcg)Injection, solutionIntramuscularSanofi Pasteur2021-02-11Not applicableEU flag
MenquadfiMeningococcal polysaccharide vaccine group W-135 (10 mcg) + Meningococcal polysaccharide vaccine group A (10 mcg) + Meningococcal polysaccharide vaccine group C (10 mcg) + Meningococcal polysaccharide vaccine group Y (10 mcg)Injection, solutionIntramuscularSanofi Pasteur2021-02-11Not applicableEU flag
MenveoMeningococcal polysaccharide vaccine group W-135 (5 mcg/0.5ml) + Meningococcal polysaccharide vaccine group A (10 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (5 mcg/0.5ml)IntramuscularGsk Vaccines S.R.L.2020-12-22Not applicableEU flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9F8QQ6EER1
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911456
RxNav
314724
FDA label
Download (83.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionMeningococcal Disease, Invasive1
4Active Not RecruitingPreventionPapillomavirus Infections1
4CompletedBasic ScienceBloodstream Infections / Meningitis / Meningococcal Disease1
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus1
4CompletedPreventionDiphtheria / Meningitis / Meningococcal sepsis / Pertussis / Tetanus1
4CompletedPreventionFlu caused by Influenza1
4CompletedPreventionMeningitis / Meningococcal Disease1
4CompletedPreventionMeningitis / Meningococcal Infections1
4CompletedPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis2
4CompletedPreventionMeningococcal Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular
SolutionIntramuscular
Injection, powder, for solutionSubcutaneous
Kit; powder, for solutionSubcutaneous
Powder, for solutionSubcutaneous
Injection, powder, for solutionIntramuscular
PowderIntramuscular
Powder, for solution; solutionIntramuscular
Injection, powder, lyophilized, for solutionIntramuscular
Kit; powder, for solutionIntramuscular
Injection, powder, for solution
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 08, 2017 20:22 / Updated on June 12, 2020 16:53